CDR-Life Inc.
CDR-Life’s technology controls and activates the body’s immune system in cancer patients to eliminate difficult-to-treat cancer tumours. To achieve this, CDR-Life is developing highly specific immunotherapies, so-called T-Cell Engagers (TCE), which target both intracellular tumour antigens and surface antigens. CDR-Life’s antibody-based TCE platform provides access to a wide range of cancer antigens. In this way, the company is building a pipeline of highly effective and highly selective therapeutics for the treatment of numerous solid tumour types.

CDR-Life Inc.
Tödistrasse 46
CH-8810 Horgen
www.cdr-life.com
info@cdr-life.com
+41 44 515 98 98

Christian Leisner
CEO and Director